Stage-specific embryonic antigen-4 is expressed in basaloid lung cancer and associated with poor prognosis

• Verfasst von: Gottschling, Sandra [VerfasserIn]
• Verfasst von: Jensen, Katrin [VerfasserIn]
• Verfasst von: Warth, Arne [VerfasserIn]
• Verfasst von: Herth, Felix [VerfasserIn]
• Verfasst von: Thomas, Michael [VerfasserIn]
• Verfasst von: Schnabel, Philipp Albert [VerfasserIn]
• Verfasst von: Herpel, Esther [VerfasserIn]
• Titel: Stage-specific embryonic antigen-4 is expressed in basaloid lung cancer and associated with poor prognosis
• Verf.angabe: Sandra Gottschling, Katrin Jensen, Arne Warth, Felix J. F. Herth, Michael Thomas, Philipp A. Schnabel, Esther Herpel
• Jahr: 2013
• Umfang: 8 S.
• Fussnoten: Gesehen am 16.04.2018
• Titel Quelle: Enthalten in: The European respiratory journal
• Ort Quelle: Lausanne : ERS, 1988
• Jahr Quelle: 2013
• Band/Heft Quelle: 41(2013), 3, Seite 656-663
• ISSN Quelle: 1399-3003
• DOI: doi:10.1183/09031936.00225711
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Basaloid nonsmall cell lung cancer
• Sach-SW: biomarker
• Sach-SW: prognosis
• Sach-SW: stage-specific embryonic antigen-4
• K10plus-PPN: 1572049006

Abstract

Basaloid carcinoma represents a rare variant of nonsmall cell lung cancer (NSCLC), which has shown a poor prognosis in a number of studies. Although it is considered to derive from a pluri- or multipotent pulmonary stem cells, little is known about the expression and clinical significance of stem cell antigens in this variant. Stage-specific embryonic antigen-4 (SSEA-4) was analysed by immunohistochemistry in 38 patients with resected early-stage basaloid NSCLC who had a median follow-up of 72.9 months. The expression of SSEA-4 was related to clinico-pathological characteristics, to the expression of the adult stem cell antigens CD117, CD133 and breast cancer resistance protein 1 (BCRP1), and to prognosis. SSEA-4 was positive in 37% of the specimens and showed no association with clinico-pathological characteristics or the expression of adult stem cell antigens. Cox proportional hazards regression analysis revealed a 6.0-fold increased risk of relapse (p = 0.001) and a 4.2-fold increased risk of disease-related mortality (p = 0.017) in SSEA-4-positive patients, while SSEA-4-negative patients showed a prognosis comparable with that of other early-stage NSCLC. SSEA-4 is expressed in a fraction of basaloid NSCLC and is associated with poor prognosis.